Despite the aforementioned limitations, we concluded that therapeutic pathways and targets for Cpn against obesity can be comprehensively screened through network pharmacology, precise quantitative transcriptomics, bioinformatics analysis, molecular docking simulation, and in vivo validation. This evidence concerns the gene CPN1 and obesity due to melanocortin 4 receptor deficiency.